BLOK™ BSA (3 Citations)
Catalog Numbers:
786-193 BLOK™ BSA in TBS [10X] 125ml
786-195 BLOK™ BSA in PBS [10X] 125ml
BLOK™ BSA 326
Catalog
Description
Size
Price(USD)
Qty
Catalog
786-193
786-193
Description
BLOK™ BSA in TBS [10X]
BLOK™ BSA in TBS [10X]
Size
125ml
125ml
$204.00
$204.00
Catalog
786-195
786-195
Description
BLOK™ BSA in PBS [10X]
BLOK™ BSA in PBS [10X]
Size
125ml
125ml
$197.00
$197.00
Protein solutions are used for blocking excess binding sites in ELISA, blotting, immunohistochemistry and other immunochemical applications. Each blocking solution will impart certain characteristics on the assay system.
Our BLOK™ BSA is a 10% solution of BSA (Bovine Serum Albumin) that serves as a protein blocking agent. It does not contain endogenous biotin; therefore, it is compatible with biotin/avidin systems and results in high signal-to-noise ratios in most systems. It is robust and shows a lack of cross-reactivity.
Our BLOK™ BSA is supplied in your choice of buffer: either in our Phosphate Buffered Saline or our Tris Buffered Saline, both 10X concentrated solutions.
Features
- [10X] BSA solution
- Convenient & Ready-to-use
- Available in your choice of TBS or PBS buffers
Applications
- For blocking Westerns, ELISA and dot Blots
| Protocol | |
| 786-193 | |
| 786-195 | |
| Material Safety Data Sheet | |
| 786-193 | |
| 786-195 | |
| Technical Literature | |
| Assay Development | A handbook for selection of products for assay development, including coated plates, blocking agents, antibodies, enzymes and antibody labeling tools. |
| Bioassays Handbook | |
| Improved Blocking for Blots & ELISA | |
| Western Blotting Handbook | From protein electrophoresis and Western transfer to blocking, probing and detection of membrane immobilized proteins. |
| Certificate Of Analysis | |
| 786-193 | |
| 786-195 | |
- Parekh, Parag et al (2022) A surrogate marker for very early-stage tau pathology is detectable by molecular magnetic resonance imaging. THERANOSTICS. https://doi.org/10.7150/thno.72258
- Tanaka, I. et al (2020) ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. Nucleic Acids Res. doi.org/10.1093/nar/gkz1213.
- Tabor-Godwin, J. et al (2012) Autophagy. 8:938